CHARLES TOWN, W.Va., Oct. 16 /PRNewswire-FirstCall/ -- ReBuilder Medical Technologies, Inc. today announced that they have agreed upon a Joint Venture with UFFE Medical, LTD, parent company to SIMpill UK to distribute the ReBuilder Medical’s unique home treatment for the skin disease Molluscum Contagiosum that affects primarily children and presents with sometimes hundreds of pimple-like lesions that can take years to resolve if not treated. UFFE Medical LTD is located at the Mortlake Business Center in London. Information about SIMpill can be found at http://www.simpill.co.uk.
(Logo: http://www.newscom.com/cgi-bin/prnh/20061128/REBUILDERLOGO )
Ann-Marie Albertsen, CEO of UFFE Medical, LTD, parent company of SIMpill explained; “My own daughter contracted Molluscum and after researching what the doctors offered I did some web research that finally lead to Dr. Phillips and http://www.molluscum.com. I ordered the product and it healed my daughter in a week’s time. Many of my neighbors’ children suffer from this highly contagious condition so I decided to see if we could provide representation here in the UK. The customs fees for shipping individual orders can cost as much as the product itself, so if we can purchase in bulk we can save that expense for our customers.”
David B. Phillips, Ph.D. CEO of ReBuilder Medical Technologies, Inc. told us, “As part of our efforts to reach out to other countries, we are glad to add UFFE Medical LTD to our growing list of distributors overseas. We hope relationships such as these will lead to joint ventures with others to provide assembly and packaging functions in their country as well. This can result in a lower price for the consumer and a lower manufacturing cost for us.”
About ReBuilder Medical Technologies, Inc.:
ReBuilder Medical Technologies, Inc. is a manufacturer of medical devices and innovative technologies founded by world-renowned medical device inventor David B. Phillips, Ph.D. The company’s flagship product is its FDA registered ReBuilder System(R), used for treating peripheral neuropathy. Unlike current therapies for neuropathy (nerve disease) that depend on prescription drugs with powerful side effects, the ReBuilder System(R) is a portable, battery- powered medical product that provides a unique, non-surgical treatment which is non-invasive, has no side effects and can actually strengthen muscles while increasing blood flow.
ReBuilder Medical Technologies, Inc. also manufactures the Phillips Molluscum Treatment System(TM) for treating the skin disease Molluscum Contagiosum which primarily affects children. This system uses its proprietary form of micronized amorphous silver ions to disable the molluscum pathogen without side effects. The company is currently performing research and development on a number of other products as well.
ReBuilder Medical Technologies, Inc. is located in Charles Town, WV. CEO, Dr. David Phillips, Ph.D. is best known for inventing the very first infrared ear thermometer. Dr. Phillips also was responsible for the GST System, which is used for the early detection of breast cancer, and the AcuPen, a hand-held device that provides the benefits of acupuncture without the use of needles.
More information on ReBuilder Medical Technologies, Inc. and its products can be found at: http://www.rebuildermedical.com.
Safe Harbor: This letter contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbors created thereby. Investors are cautioned that all forward-looking statements involve risks and uncertainty, including without limitation, the ability of the Company to successfully implement its turnaround strategy, changes in costs of raw materials, labor, and employee benefits, as well as general market conditions, competition and pricing. Although the Company believes that the assumptions underlying the forward-looking statements contained herein are reasonable, any of the assumptions could be inaccurate, and therefore, there can be no assurance that the forward-looking statements included in this letter will prove to be accurate. In light of the significant uncertainties inherent in the forward- looking statements included herein, the inclusion of such information should not be regarded as representation by the Company or any other person that the objectives and plans of the Company will be achieved. In assessing forward- looking statements included herein, readers are urged to carefully read those statements. When used in the Annual Report on Form 10-K, the words “estimate,” “anticipate,” “expect,” “believe,” and similar expressions are intended to be forward-looking statements.
CONTACT: Daena Carter of ReBuilder Medical Technologies, Inc.,
+1-304-725-2202
Web site: http://www.rebuildermedical.com/
http://www.molluscum.com/
http://www.simpill.co.uk/
